Exited position

Warren Buffett’s Merck (MRK) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Berkshire HathawayVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2020Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares28.70MHighest verified quarter-end share count
Quarters reported4Verified quarters with shares above zero
What happened?

Berkshire Hathaway first reported Merck in Q3 2020. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Berkshire Hathaway sold the entire position in Q3 2021, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2021
Sold the entire position−9.16M shares · No shares reported at quarter-end
Q2 2021
Sold 48.8% of the position−8.73M shares · 9.16M shares remained
Filing context

Quarter-end price $77.77 · Estimated holding basis $82.70

Q1 2021
Sold 37.7% of the position−10.82M shares · 17.88M shares remained
Filing context

Quarter-end price $77.09 · Estimated holding basis $82.70

Q4 2020
Bought 28.1% more+6.29M shares · 28.70M shares reported after the change
Filing context

Quarter-end price $81.80 · Estimated holding basis $82.70

Q3 2020
New position+22.40M shares · 22.40M shares reported
Filing context

Quarter-end price $82.95 · Estimated holding basis $82.95

Portfolio importance

How important was Merck in Berkshire Hathaway’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.2%Q2 2021
Last reported rank#28of 44 reported positions
Peak portfolio weight0.9%Q4 2020
Best historical rank#16Q4 2020
At peak importanceQ4 2020
MRK
0.9%
Largest holding
43.6%
Cross-investor discovery

Who else owns Merck?

Also reported by 4 other tracked investors in their latest verified filings.

Christopher BloomstranSemper Augustus Investments Group LLC
MRK0.6% of reported portfolio
Joel GreenblattGotham Asset Management
MRK0.2% of reported portfolio
Ray DalioBridgewater Associates, LP
MRK0.0% of reported portfolio
Explore Merck across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$143.932026-09-11

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Merck stock page →

This tracker follows Berkshire Hathaway’s Form 13F disclosures. It is not Warren Buffett’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.